The first phase 2 antithrombotic efficacy and safety results for the novel anti-activated coagulation factor XI [anti-XIa] monoclonal antibody are reported in Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty; The FOXTROT randomized clinical trial JAMA. 2020;323:130–9. doi:10.1001/jama.2019.20687. This is an exciting new approach that may provide anticoagulation with reduced bleeding risk.